Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Histogenics Cp (HSGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,117
  • Shares Outstanding, K 62,030
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,410 K
  • 36-Month Beta 0.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.95
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.23
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +42.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.41 +34.17%
on 12/03/18
0.59 -6.29%
on 11/26/18
+0.10 (+23.34%)
since 11/16/18
3-Month
0.38 +46.69%
on 11/15/18
1.43 -61.53%
on 10/04/18
+0.01 (+1.87%)
since 09/17/18
52-Week
0.38 +46.69%
on 11/15/18
3.35 -83.58%
on 03/15/18
-1.31 (-70.42%)
since 12/15/17

Most Recent Stories

More News
Histogenics and FDA Continue to Discuss NeoCart(R) Phase 3 Clinical Trial Data and Potential Regulatory Pathway

Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on...

HSGX : 0.55 (unch)
New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Intersections, Inc. (NASDAQ:INTX),...

GLEC : 0.0014 (+40.00%)
SEAC : 1.29 (-3.73%)
PRGX : 9.23 (-0.43%)
EEI : 11.59 (-2.11%)
TACT : 8.69 (-5.65%)
INTX : 3.64 (-0.82%)
HSGX : 0.55 (unch)
Histogenics: 3Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Histogenics Corp. (HSGX) on Thursday reported third-quarter net income of $10.7 million, after reporting a loss in the same period a year earlier.

HSGX : 0.55 (unch)
Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results

EQNX::TICKER_START (Nasdaq:HSGX), EQNX::TICKER_END

HSGX : 0.55 (unch)
Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018

Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its third quarter...

HSGX : 0.55 (unch)
Histogenics Corporation Announces Closing of Public Offering of Common Stock and Warrants

Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the closing of its previously announced underwritten public offering of...

HSGX : 0.55 (unch)
Histogenics Corporation Announces Pricing of Public Offering of Common Stock and Warrants

Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the pricing of an underwritten public offering of 26,155,000 shares of its...

HSGX : 0.55 (unch)
Histogenics Corporation Announces Proposed Public Offering of Common Stock and Warrants

Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced that it intends to offer and sell shares of its common stock and accompanying...

HSGX : 0.55 (unch)
Histogenics to Meet With FDA to Discuss NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today announced that the U.S....

HSGX : 0.55 (unch)
Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart(R) in Patients With Knee Cartilage Damage

â?' Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After Treatment as Compared...

HSGX : 0.55 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade HSGX with:

Business Summary

Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 0.60
1st Resistance Point 0.57
Last Price 0.55
1st Support Level 0.52
2nd Support Level 0.50

See More

52-Week High 3.35
Fibonacci 61.8% 2.21
Fibonacci 50% 1.86
Fibonacci 38.2% 1.51
Last Price 0.55
52-Week Low 0.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar